News

The National Institute for Health and Care Excellence2d
Technology for children and young people with chronic tic disorders and Tourette syndrome recommended
Draft guidance issued for consultation recommends two technologies to help people manage their condition. A digital therapy that could reduce the severity of the symptoms of chronic tic disorders and ...
National Institute for Health and Care Excellence3d
Published guidance, NICE advice and quality standards
Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment HTE24 1 May 2025 1 May 2025 ...
National Institute for Health and Care Excellence4d
Obsessive-compulsive and related disorders: assessment and management
Your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your ...
National Institute for Health and Care Excellence4d
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence4d
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
Osimertinib with pemetrexed and platinum-based chemotherapy (Tagrisso) is available on the NHS as a possible treatment for advanced non-small-cell lung cancer that has not been treated before. It is ...
National Institute for Health and Care Excellence4d
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
National Institute for Health and Care Excellence4d
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...
National Institute for Health and Care Excellence4d
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
Osimertinib (Tagrisso, AstraZeneca) with pemetrexed and platinum-based chemotherapy is indicated for 'the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 ...
National Institute for Health and Care Excellence4d
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
Osimertinib with pemetrexed and platinum-based chemotherapy is recommended, within its marketing authorisation, as an option for untreated advanced non-small-cell lung cancer (NSCLC) in adults whose ...